Table 2.
Association of IRF5 rs13242262A/T and rs10488630A/G with hepatitis B virus-related liver cirrhosis n (%)
| IRF5 variants | HC, n = 242 | CHB, n = 99 | LC, n = 131 | HCC, n = 149 |
LC vs CHB |
|
| OR (95%CI) | P value | |||||
| rs13242262 A/T | ||||||
| AA | 67 (27.7) | 27 (27.3) | 32 (24.4) | 45 (30.2) | Reference | |
| AT | 119 (49.2) | 59 (59.6) | 65 (49.6) | 77 (51.7) | 1.0 (0.5-2.0) | NS |
| TT | 56 (23.1) | 13 (13.1) | 34 (26.0) | 27 (18.1) | 3.1 (1.2-7.8) | 0.014 |
| Allele | ||||||
| A | 253 (52.3) | 113 (57) | 129 (49.2) | 165 (55.3) | Reference | |
| T | 231 (47.7) | 85 (43) | 133 (50.8) | 133 (44.7) | 1.5 (1.1-2.3) | 0.040 |
| Dominant | ||||||
| AA | 67 (27.7) | 27 (27.3) | 32(24.4) | 45 (30.2) | Reference | |
| AT + TT | 175 (72.3) | 72 (72.7) | 99 (75.6) | 104 (69.8) | 1.3 (0.7-2.6) | NS |
| Recessive | ||||||
| AA + AT | 186 (76.9) | 86 (87) | 97 (74.0) | 122 (81.9) | Reference | |
| TT | 56 (23.1) | 13 (13) | 34 (26.0) | 27 (18.1) | 2.8 (1.3-5.9) | 0.0057 |
| rs10488630 A/G | ||||||
| AA | 115 (47.5) | 58 (58.6) | 59 (45.1) | 73 (49.0) | Reference | |
| AG | 104 (43.0) | 36 (36.4) | 56 (42.7) | 63 (42.3) | 1.6 (0.9-2.9) | 0.100 |
| GG | 23 (9.5) | 5 (5.0) | 16 (12.2) | 13 (8.7) | 3.0 (1.0-9.5) | 0.045 |
| Allele | ||||||
| A | 334 (69) | 152 (76.8) | 174 (66.4) | 209 (72.3) | Reference | |
| G | 150 (31) | 46 (23.2) | 88 (33.6) | 89 (27.7) | 1.7 (1.1-2.6) | 0.019 |
| Dominant | ||||||
| AA | 115 (47.5) | 58 (58.6) | 59 (45.0) | 73 (49) | Reference | |
| AG + GG | 127 (52.5) | 41 (41.4) | 72 (55.0) | 76 (51) | 1.8 (1.0-3.2) | 0.035 |
| Recessive | ||||||
| AA + AG | 219 (90.5) | 94 (94.9) | 115 (87.8) | 136 (91.3) | Reference | |
| GG | 23 (9.5) | 5 (5.1) | 16 (12.2) | 13 (7.8) | 2.4 (0.8-7.2) | 0.100 |
HC: Healthy controls; CHB: Chronic hepatitis B; LC: Liver cirrhosis; HCC: Hepatocellular carcinoma.